PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS) +54%; announced FDA authorization to proceed with VANGARD, a potentially pivotal clinical trial to evaluate PB1046 as a treatment for hospitalized COVID-19 patients who are at high risk for rapid clinical deterioration and acute respiratory distress syndrome (ARDS).

Triumph Group (NYSE: TGI) +24%; reported Q4 EPS of $0.69, $0.05 better than the analyst estimate of $0.64. Revenue for the quarter came in at $693.1 million versus the consensus estimate of $660.1 million.

Dollar Tree (NASDAQ: DLTR) +9.5%; reported Q1 EPS of $1.04, $0.13 better than the analyst estimate of $0.91. Revenue for the quarter came in at $6.29 billion versus the consensus estimate of $6.11 billion.

Toll Brothers (NYSE: TOL) +7.3%; reported Q2 EPS of $0.59, $0.11 better than the analyst estimate of $0.48. Revenue for the quarter came in at $1.55 billion versus the consensus estimate of $1.57 billion.

Alexion Pharma (NASDAQ: ALXN) +7%; Alexion Pharma (NASDAQ: ALXN) and Amgen (NASDAQ: AMGN) reached Soliris IPR settlement, according to new documents posted on PTAB website overnight.

Spirit AeroSystems Holdings, Inc. (NYSE: SPR) +7%; gains on Boeing 737 MAX resumed production news

Workday (NASDAQ: WDAY) +6%; reported Q1 EPS of $0.44, $0.03 worse than the analyst estimate of $0.47. Revenue for the quarter came in at $1.02 billion versus the consensus estimate of $1 billion. Now expect fiscal 2021 subscription revenue in a range of $3.67 billion to $3.69 billion. We expect second-quarter subscription revenue of $913.0 million to $915.0 million. We are raising our fiscal 2021 non-GAAP operating margin guidance to 16.0%.

Boeing (NYSE: BA) +4.8%; has resumed production of the 737 MAX at the company’s Renton, Washington factory. The 737 program began building airplanes at a low rate as it implements more than a dozen initiatives focused on enhancing workplace safety and product quality.

Hertz Global (NYSE: HTZ) -15.3%; Carl Icahn Says He Sold Equity Position in Hertz Global (HTZ) at Significant Loss, Continues to Have Faith in Company's Future

Iovance Biotherapeutics (NASDAQ: IOVA) -13%; announced that it intends to offer and sell $500 million of its common stock, subject to market and other conditions, in an underwritten public offering.

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) -11%; announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, $250,000,000 of its common stock. All of the shares are being offered by Arena. In addition, Arena intends to grant the underwriters of the offering a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Viela Bio (NASDAQ: VIE) -5.6%; today announced the pricing of an underwritten public offering of 3,600,000 shares of its common stock at a price to the public of $47.00 per share.

Twitter (NYSE: TWTR) -5.1%; Trump's executive order targets political bias at Twitter and Facebook